{Reference Type}: Case Reports
{Title}: Tezepelumab for refractory eosinophilic granulomatosis with polyangiitis-related asthma.
{Author}: Vincent-Galtié N;Marquant Q;Catherinot E;Ackermann F;Magnan A;Tcherakian C;Groh M;
{Journal}: Respir Res
{Volume}: 25
{Issue}: 1
{Year}: 2024 Jul 11
暂无{DOI}: 10.1186/s12931-024-02888-x
{Abstract}: Conventional immunosuppressants are ineffective for the management of EGPA-related asthma. Tezepelumab is a human monoclonal antibody that inhibits thymic stromal lymphopoietin (TLSP) that has proven efficacy in several phase 3 studies for the treatment of asthma. We treated with off-label tezepelumab the first two patients with severe refractory EPGA-related asthma. These preliminary findings suggest that targeting upstream signaling of the T2 inflammatory pathway can improve symptoms, reduce BVAS and increase Asthma Control Test scores, even in patients with refractory asthma who have failed several previous lines of treatment. Nevertheless, by analogy with dupilumab-induced IL-4/13 blockade, the persistence of sputum eosinophilia (reported in both patients) raises questions as to whether TSLP inhibition could lead to a rebound of eosinophilia and potentially to eosinophil-related symptoms in patients with EGPA.